A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52 WEEK OPEN LABEL EXTENSION

Registry ID

CR845-CLIN3103

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

CARA THERAPEUTICS

Start date

2019-07-15

Completion date

2020-06-04

Last update

2018-07-12

Conditions

• PRURITIS

Related clinical trials

• AN EXPLORATORY PROOF OF CONCEPT STUDY TO ASSESS THE PHARMACOKINETICS/PHARMACODYNAMICS OF NEMOLIZUMAB (CD14152) IN ADULT PARTICIPANTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB FOR THE TREATMENT OF PRURITUS OF LICHEN SIMPLEX CHRONICUS (LSC) IN ADULTS
• ¿MASTER PROTOCOL OF TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP STUDIES TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)¿
• LONG-TERM SAFETY AND TOLERABILITY STUDY OF LINERIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PARTICIPANTS WITH PRIMARY BILIARY CHOLANGITIS.

View on source registry